Any controlled human study of isolated CBC. Until one exists there is no clinical record to grade, and every CBC citation stays off-registry.
Cannabinoid pillar · the chromene branch
Cannabichromene (CBC).
Is there human or clinical evidence for CBC?
Essentially none: no controlled human trial of CBC has been run, which leaves it untested rather than tested and negative. evidence state: No primary evidence
Three enzymes compete for the plant’s supply of CBGa. Two of them make the famous molecules. CBC comes off the third branch, the one that leads to neither THC nor CBD, and it is better understood in the lab than most of its minor-cannabinoid peers: settled chemistry, well-characterised pharmacology. The gap is a single controlled trial in people. With a compound like this, the temptation is to let a receptor assay stand in for a clinical result, and that is exactly the move the evidence won’t support.
Evidence library·21 studies·updated 9 August 2026·How we check
On this page12 sections
Where it comes from
One substrate, three enzymes, three destinations.
CBC is a main product in its own right: one of three committed routes out of the plant’s central branch point.
The branch point
The synthases work on CBGa, the acid, rather than neutral CBG, and three of them compete for it: THCA synthase, CBDA synthase and CBCA synthase. The chromene arm makes CBCA, which decarboxylates to CBC with heat, just as CBGa decarboxylates to CBG. Because all three enzymes draw on one pool, a plant’s CBC content comes down to which branch wins; CBC has no pathway of its own. The CBGa monograph sets out the branch point in full.
Ask the supplier: six questions about CBC.
Six questions to put to a supplier, each followed by the position the registry or this compound's page already holds, in its own words. The questions ask what the supplier states; none asks what anyone should take. Informational only, not medical or legal advice.
- 1What human data does the supplier cite for the product?
- The pillar's answer: “The published work cited here stops at cells and rodents”. A human claim on a CBC label has no source behind it.On the CBC page →
- 2How many milligrams of CBC per serving, and against what?
- There is no human figure to size it against; what is missing is “How CBC is absorbed, what dose matters, and whether the concentrations that work in a dish can be reached in a person at all.”On the CBC page →
- 3On what basis does the label say non-intoxicating?
- Identity, on the pillar: “Non-intoxicating.” is part of CBC's chemical-identity row, with its formula and molar mass.On the CBC page →
- 4Does the label borrow receptor activity from CBD, CBG or THC?
- CBC's laboratory profile is its own: activity at those channels stays with those compounds, and “a formulator can't borrow it for CBC”.On the CBC page →
- 5Does the supplier cite the mouse colitis paper as an effect?
- Preclinical, and the pillar says what it does not show: “Any effect in people, or anything about inflammatory bowel disease in humans.”Not graded in our registryPMID 23373571 · On the CBC page →
- 6What does the supplier's evidence base look like beside the registry's?
- The registry's own row reads “Catalogue in progress: no CBC record in our registry yet”, so every CBC citation the supplier offers is one the site has not graded.On the CBC page →
Take the answers to the paperwork: Read a COA, then test the label wording. How the site grades what it holds is on How we grade.
Knowledge boundary
What is established about CBC, and what is not
Established
- ✓Chemical identityC₂₁H₃₀O₂, molar mass ≈ 314.46 g/mol. Non-intoxicating.
- ✓One of three branches off a single substrateCBCA synthase converts the shared CBGa substrate into CBCA, which decarboxylates to CBC. THCA and CBDA leave the same branch point by the other two routes, with all three synthases drawing on one pool, so the amount of CBC a plant carries depends on which branch wins.
- ✓Characterised at TRPA1, and inactive at several other channelsIn laboratory assays CBC acts at TRPA1 and inhibits anandamide cellular uptake. It leaves TRPV1 and TRPV2 unactivated, and it was the one phytocannabinoid in its test panel that failed to antagonise TRPM8. So activity reported for CBD, CBG or THC at those channels stays with those compounds; a formulator can't borrow it for CBC.
Not yet established
- —Any controlled human trial of isolated CBCThe published work cited here stops at cells and rodents, and none of it establishes an effect in a person.
- —Which target carries the effect in a living animalIn recombinant cells CBC behaves as a low-potency CB2 agonist with little CB1 activity. Mice tell a different story: its anti-oedema effects survived CB1 and CB2 antagonists, and its gut effects survived both cannabinoid-receptor and TRPA1 antagonists. The target seen in cells has yet to be matched to the mechanism in the animal.
- —A CBC record in our evidence registryUntil one is added, the CBC filter in the Research Library reads zero rather than sitting blank.
- —Human pharmacokineticsHow CBC is absorbed, what dose matters, and whether the concentrations that work in a dish can be reached in a person at all.
Characterised and evidenced are different things
For a minor cannabinoid, the established side is unusually strong: a defined molecular target, and a set of channels CBC demonstrably leaves alone. The other side still holds no human data. A compound can be well characterised in a dish and entirely untested as a treatment, and CBC is the clearest case of it anywhere in the Atlas. Those gaps are absences, not findings against CBC, and our ladder reserves Not-supported for evidence that weighs against a claim.
The preclinical record
What has actually been tested, and in what.
The cited record fits in three papers, and it helps to know what each one measured before reading any of them. The strongest pairs a mechanism with an outcome in the same mouse. The easiest to misread tracked how much of a channel the gut expressed, which is a different question from what CBC did to the channel. The third is cells in a dish. None of the three is in people.
2013
The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis
What was actually tested: Two systems in one paper. In vitro, mouse peritoneal macrophages were activated with LPS, and nitrite levels were measured as a readout of nitric oxide production. In vivo, colitis was induced in mice with dinitrobenzene sulphonic acid (DNBS) and scored by myeloperoxidase activity, histology and immunohistochemistry.
In macrophages, CBC significantly reduced LPS-stimulated nitrite levels. Cannabinoid-receptor and TRPA1 agonists (carvacrol and cinnamaldehyde) mimicked the effect, and CB₁ antagonists enhanced it; the authors describe tonic CB₁ signalling as negatively coupled to the effect. CBC did not significantly change the LPS-induced rises in anandamide, iNOS, COX-2 or cannabinoid-receptor expression, but it did raise oleoylethanolamide levels. In the mice, CBC ameliorated DNBS-induced colonic inflammation.
What it shows: That CBC acts at TRPA1, lowers nitric oxide production in activated mouse macrophages, and reduced inflammation in one chemically induced mouse model of colitis.
What it does NOT show: Any effect in people, or anything about inflammatory bowel disease in humans. DNBS colitis is a chemical injury to a mouse colon, a different thing from Crohn's disease or ulcerative colitis. A result in this model earns further study and says nothing yet about treatment.
Caveat: Preclinical only. Its nearest CBG counterpart is Borrelli 2013, the murine colitis study our registry holds; the designs are similar, and both stop at the mouse.
Preclinical · mouse macrophages + murine colitis modelNot graded in our registry
2011
Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation
What was actually tested: The paper tested cannabinoid activity at thermosensitive TRP channels in HEK-293 cells expressing rat recombinant TRPV3 or TRPV4. Separately, it measured TRP channel mRNA by quantitative RT-PCR in the jejunum and ileum of mice given vehicle or the pro-inflammatory agent croton oil.
The paper describes CBC as TRPV-inactive, so its CBC result comes from the expression arm. In croton-oil-treated mice, CBC reduced TRPV1β, TRPV3 and TRPV4 mRNA in the jejunum, and TRPV3 and TRPV4 mRNA in the ileum. The authors conclude that cannabinoids can affect both the activity and the expression of TRPV1–4 channels.
What it shows: That CBC changed the expression of several TRPV channels in inflamed mouse intestine, which is a different mechanism from activating or desensitising a channel directly.
What it does NOT show: A clinical effect, or any direct action of CBC on TRPV channels; the activation assays in this paper found it TRPV-inactive. A change in mRNA in a mouse gut is a mechanistic observation, not an outcome.
Caveat: Often misdated and misdescribed: the paper is from 2011, not 2012, and its recombinant channels are rat, not human. Our CBG pages cite the same record for its CBG findings. The CBC result is a different finding from the same paper, so it appears in prose rather than as a graded CBC record.
Preclinical · gene expression in mouse intestineNot graded in our registry
2013
The effect of cannabichromene on adult neural stem/progenitor cells
What was actually tested: Adult mouse neural stem/progenitor cells (NSPCs), cultured and differentiating in vitro. The study compared three non-THC phytocannabinoids (cannabidiol, cannabigerol and cannabichromene) using viability, marker expression (nestin, GFAP), ERK1/2 phosphorylation and ATP levels as readouts.
CBC improved the viability of mouse NSPCs during differentiation. Nestin, a progenitor marker, went up, and GFAP, an astrocyte marker, went down. CBC stimulated ERK1/2 phosphorylation, with a slower onset than typical MAPK stimulation. A selective adenosine A₁ receptor antagonist blocked both the ERK1/2 phosphorylation and the rise in nestin, which points to adenosine signalling. ATP levels were also higher when CBC was present during differentiation. The authors' summary is that CBC “raises the viability of NSPCs while inhibiting their differentiation into astroglia”.
What it shows: That CBC changed the viability and differentiation of mouse neural progenitor cells in culture, apparently involving adenosine A₁ signalling.
What it does NOT show: Neuroprotection, cognitive benefit, or any effect on a human brain. These are cells in a dish, with a whole clinical development programme between them and a person.
Caveat: In vitro only, and a single study. It earns its place as one of the few papers to study CBC on its own rather than as one entry in a screening panel.
In vitro · mouse neural stem/progenitor cellsNot graded in our registry
A parallel with CBG, and its limit
Put the colitis result beside the CBG colitis study in our registry (Borrelli 2013) and the two look alike: a similar model, a similar direction of effect. That makes CBC worth watching; it does not make the two equivalent. The CBG study is a graded registry record; the CBC paper is cited in prose, because no CBC record has passed the gate. Underneath sits a harder problem. In living animals, antagonists of the receptors CBC engages in a dish failed to block its effects, so what drives them is still unknown.
Against the mother cannabinoid
Two branches from the same substrate.
| Property | CBC | CBG |
|---|---|---|
| Origin | From CBCA (CBCA-synthase branch off CBGa) | Decarboxylation of CBGa |
| Molecular formula | C₂₁H₃₀O₂ · ≈ 314.46 | C₂₁H₃₂O₂ · 316.48 |
| Characterized pharmacology | TRPA1 agonist; inhibits anandamide cellular uptake (published in-vitro work cited below, not yet a graded registry record) | α2, 5-HT1A, CB1, TRP (in vitro) |
| Human evidence | None catalogued in our registry yet (catalogue in progress) | One small acute trial (Low) |
Safety
What is known about CBC safety, and what is not?
Precautionary by default
The safety question comes down to what has been measured in people, and for isolated CBC that is no controlled human safety data: tolerability, dosing and chronic use are all untested. The rodent work generally used high doses, and an animal dose does not translate to a human one. Being non-intoxicating says nothing about safety either. Nothing here is medical advice, and nobody should change or stop a prescribed medication on the strength of it. Safety & reporting.
Research roadmap
What new evidence would change what we say about CBC?
Human pharmacokinetics, to settle whether the concentrations active in these cell and rodent systems can be reached in a person.
Independent replication of the murine colitis result, ideally by a group with no link to the original authors.
A CBC record in our evidence registry, which would move the Research Library's CBC filter off zero.
Common questions
40 questions people ask about CBC.
CBC is one of the plant's major cannabinoids, and in people it is barely studied at all. Its chemical identity, non-intoxicating status, biosynthesis and laboratory (in-vitro) pharmacology are verified and carry an evidence grade. Its effects, benefits, or uses (mood, inflammation, pain, "entourage") are claims made by third parties such as manufacturers, media or preliminary research, and CBG Atlas does not make, adopt, or affirm them. Every grade chip links to /evidence, which explains how grades are assigned, and thin or missing evidence is marked as such. Not medical or legal advice. The full disclaimer sits at the foot of the page.
How these are graded · 20 of 40 on the ladder
20 carry a rung on the six-rung evidence ladder. 13 carry an evidence state in place of a rung, most often no primary evidence: our registry has no study on that question yet. A state marks a gap in coverage, a different thing from the not supported grade.
Identity & origin
Show the answers 4
What is CBC?
CBC (cannabichromene) is a non-intoxicating phytocannabinoid, one of the major cannabinoids the cannabis plant builds from CBGA alongside CBG, CBD and THC. Its chemistry is Established. Its effects in people are another story: no controlled human trial of CBC has been published, so every therapeutic claim made for it remains unconfirmed, catalogue in progress, with no grade.
What does CBC (cannabichromene) mean?
"Cannabichromene" names the molecule's structure: a cannabinoid built around a chromene ring system, abbreviated to "CBC". The name is pure chemistry, a description of structure rather than of any effect. CBC is one of the plant's major phytocannabinoids, non-intoxicating, and chemically distinct from CBD, CBG and THC.
Where does CBC come from — the third major branch from CBGA?
From CBGA, the plant's parent "mother" cannabinoid. The enzyme CBCA synthase converts CBGA into CBCA, opening a third major branch beside the THCA and CBDA branches, and heat then turns CBCA into CBC. The THCA and CBDA synthases also yield some CBCA (Zirpel 2018).
Is CBC natural or synthetic?
Natural. The cannabis or hemp plant makes CBCA, and heat decarboxylates it into CBC. Chemists can also make CBC synthetically or semi-synthetically for research and some products, but the CBC in hemp extracts is a naturally occurring plant compound.
Psychoactivity
Show the answers 4
Does CBC get you high?
No. CBC is non-intoxicating, and that status is well established. THC's high comes from activating the CB1 receptor, the mechanism behind cannabis intoxication, and CBC is not known to act as a CB1 receptor agonist.
Is CBC psychoactive?
In the intoxicating sense, no: CBC is non-intoxicating and non-impairing, with none of THC's high. "Psychoactive" is a broader word, covering anything that affects the brain, and some cannabinoids may subtly influence mood without intoxicating. Whether CBC does anything of the kind in people remains an open question.
What does CBC feel like?
Controlled human studies have not characterised CBC's subjective effects, so any description is guesswork. Some users and marketers call it mild, often in full-spectrum products, but those impressions are anecdotes rather than established effects. CBC produces no THC-like high. (Not medical advice.)
Is CBC sedating, energizing, or neutral?
Not established. Controlled human research has not shown whether CBC is sedating, energizing or neutral. CBC is non-intoxicating, and the "relaxing" impression some people report is anecdotal, often from full-spectrum products that contain other compounds and terpenes. A sedation claim for CBC has no evidence behind it. (Not medical advice.)
Legality
Show the answers 4
Is CBC legal?
That depends on where you are and where the CBC came from. In the US, CBC derived from hemp (≤0.3% Δ9-THC) is broadly treated as federally legal, though state rules and product-class rules vary. Elsewhere, food and supplement use may be restricted. Verify current local law. (Not legal advice.)
Is CBC legal federally (2018 Farm Bill)?
Generally yes, with one caveat. The 2018 Farm Bill legalised hemp and its derivatives containing at most 0.3% Δ9-THC by dry weight, which generally covers hemp-derived CBC in the US. The catch is food law: the FDA has not approved CBC as a food or supplement ingredient, so a lawful hemp derivative is not automatically a lawful food ingredient, and the rules are still evolving. Verify current law. (Not legal advice.)
Is CBC legal in my state?
It varies by state, and only your state's current rules can settle it for your product. Many US states follow the federal hemp framework, but some restrict certain hemp-derived or converted cannabinoids, and rules differ by product class (food, supplement, inhalable). Check your state's current cannabis and hemp regulations. (Not legal advice.)
Is CBC legal in the UK, EU, or Canada?
Generally not as a food or supplement that can be sold freely. In the UK and EU, extracted cannabinoids such as CBC fall under "novel food" rules, so food and supplement sales need authorisation and remain restricted. Canada regulates phytocannabinoids, CBC included, under the Cannabis Act rather than as open-market supplements. Status changes over time; verify with official sources. (Not legal advice.)
Effects & benefits
Show the answers 4
What are the benefits of CBC?
No benefit of CBC has been established in humans. What exists is lab work: in laboratory (in-vitro) studies CBC acts on the TRPA1 channel, inhibits cellular uptake of anandamide (De Petrocellis 2011) and shows antibacterial activity (Appendino 2008). Those are mechanisms seen in a dish, graded Emerging, and not benefits shown in a person. The mood, pain and inflammation claims sellers make rest on preclinical work alone. (Not medical advice.)
What is CBC used for?
Mostly as an ingredient. CBC goes into full-spectrum hemp products and minor-cannabinoid formulations, marketed alongside CBD, with sellers promoting it for mood, inflammation and skin. None of those uses is established in humans. The research behind those uses is preclinical (lab and animal) only, so a brand selling them has only animal and cell studies to cite. (Not medical advice.)
Does CBC help with mood, inflammation, or pain?
Not in humans, so far. Some preclinical (animal and lab) studies report antidepressant-like, anti-inflammatory or pain-related effects, and CBC is widely marketed on that basis, yet no controlled human trial has confirmed any of them. The popular "CBC antidepressant" claim rests on preclinical work alone, and our registry holds no primary evidence of a benefit in people. (Not medical advice.)
Is there human or clinical evidence for CBC?
Essentially none: no controlled human trial of CBC has been run, which leaves it untested rather than tested and negative. The research that exists is preclinical, cell and animal studies of mechanisms such as CBC's action on the TRPA1 channel (De Petrocellis 2011). CBC's efficacy and safety in humans remain catalogue in progress. (Not medical advice.)
Safety & side effects
Show the answers 4
Is CBC safe?
Not established, because there are no controlled human safety trials of CBC. CBC is non-intoxicating and its record so far carries no major safety alarms, but long-term effects, higher doses and drug interactions are all unstudied. Anyone taking medication or living with a health condition should check with a clinician first. (Not medical advice.)
What are the side effects of CBC?
Nobody has a reliable list, because CBC's side effects in humans have not been formally studied. CBC is non-intoxicating, but its effects, tolerability and interactions remain uncharacterised, and products often contain other cannabinoids too. Consult a clinician with any concerns. (Not medical advice.)
Can you take too much CBC?
Nobody can define "too much" yet. Human dosing of CBC is unstudied, so there is no established safe or maximum dose, and we give no dosing advice. As a general principle, more of any supplement is not better. Discuss any cannabinoid use with a healthcare professional. (Not medical advice.)
Does CBC interact with medications?
It might, and CBC-specific human data on drug interactions are essentially absent. Cannabinoids as a class can affect drug-metabolising enzymes, which may matter for anyone on other medication. With CBC uncharacterised on this front, check with a clinician or pharmacist before combining it with any drug. (Not medical advice.)
Drug testing
Show the answers 3
Will CBC show up on a drug test?
Pure CBC on its own should pass unnoticed, because standard drug tests look for THC and its metabolite (THC-COOH). The real risk sits in the product: full- or broad-spectrum CBC products can contain trace THC, and that can cause a failed test. (Not medical advice.)
Does CBC contain THC?
No. CBC (cannabichromene) is a separate molecule, chemically distinct from THC, and contains none. A CBC product can still contain THC if it is full- or broad-spectrum and made from cannabis or hemp, so check the THC figure on the certificate of analysis (COA).
Can CBC make you fail a drug test?
Unlikely from the molecule itself, since drug tests are built to detect THC. Many CBC products are full- or broad-spectrum, though, and may contain trace THC, which is what triggers a positive. Read the batch certificate of analysis (COA) before buying, and treat a missing COA as a reason to walk away. (Not medical advice.)
Usage & dosing
Show the answers 4
How do you take CBC?
The same ways as CBD: oils and tinctures held under the tongue and then swallowed, capsules, edibles, topicals for the skin, or vaporised products. CBC mostly reaches the shelf inside full-spectrum or minor-cannabinoid blends rather than on its own. We give no dosing advice. (Not medical advice.)
What products or forms does CBC come in?
Mainly full-spectrum and "minor cannabinoid" hemp products: oil tinctures, softgels and capsules, gummies and edibles, topical balms and creams, and vape or concentrate formats. Pure CBC isolate exists but is less common than CBD. Availability and quality swing widely, so check the certificate of analysis (COA).
How much CBC should I take?
Nobody knows yet, because human dosing of CBC is unstudied, and we don't provide dosing advice. Products print their own serving sizes, and those sizes lack any clinical validation. Anyone considering CBC should discuss it with a healthcare professional. (Not medical advice.)
How long does CBC take to work or last?
CBC-specific timings have not been measured, because its pharmacokinetics (onset, duration, absorption) remain uncharacterised in humans. As a general rule of route, and not a claim about CBC, inhaled and under-the-tongue products tend to act sooner, while swallowed edibles act later but last longer. (Not medical advice.)
Comparisons
Show the answers 4
CBC vs CBD — what's the difference?
Structure, lab pharmacology and, above all, the depth of research. Both are non-intoxicating phytocannabinoids made from CBGA, but they are distinct molecules, and CBC notably acts as a TRPA1-channel agonist in vitro (De Petrocellis 2011). CBD is far more studied and has an approved epilepsy medicine; CBC has essentially no human data. (Not medical advice.)
CBC vs THC — what's the difference?
Intoxication, mainly. THC activates the CB1 receptor and intoxicates; CBC is non-intoxicating. Both come from CBGA, through the THCA and CBCA branches respectively. THC is heavily studied and has approved medicines, while CBC's effects in people are largely unstudied. (Not medical advice.)
CBC vs CBG — how do they compare?
They share an origin and little else. Both are non-intoxicating and both trace back to CBGA: CBG is the decarboxylated "mother" itself, while CBC sits on a separate branch (via CBCA), and the two show different lab pharmacology. Human evidence is thin for both: CBG has one small human trial in our registry, and CBC has essentially none. (Not medical advice.)
Which is better for inflammation, CBC or CBD?
Nobody can say, because no head-to-head human comparison exists, and any "better for inflammation" claim is unsupported. Both show anti-inflammatory-related activity only in preclinical (lab and animal) studies, still unconfirmed in people, and no primary evidence we hold ranks one above the other. CBD is more studied overall, though a larger literature is a different thing from proof of superiority. (Not medical advice.)
Chemistry & production
Show the answers 4
What is CBC's formula and structure?
CBC's molecular formula is C21H30O2, its molecular weight about 314.46 g/mol, and its CAS 20675-51-8. A chromene-type cannabinoid, it is built on a 2H-chromene ring with a pentyl side chain. CBC, CBD and THC are structural isomers: the same formula (C21H30O2) arranged in different ways.
How is CBC made or extracted?
In the plant, CBCA synthase converts CBGA into CBCA, which loses CO2 when heated (decarboxylation) and becomes CBC. Commercial producers extract it from hemp or cannabis biomass (for example by CO2 or ethanol extraction) and purify it by chromatography, or make it synthetically. The plant route is verified biochemistry (Zirpel 2018).
Is CBC a major cannabinoid or a minor one?
Both, depending on what you count. By structure and biosynthesis CBC ranks as a "major" phytocannabinoid, one of the principal branches the plant builds from CBGA alongside CBG, CBD and THC. By abundance it is minor: most cultivars contain only small amounts, so the market treats it as a minor cannabinoid. One label tracks biosynthesis, the other quantity, and both are Established.
What is CBCA — does CBC come from an acid?
Yes. CBC starts life as CBCA (cannabichromenic acid), its acidic form in the raw plant. The plant makes CBCA from CBGA via CBCA synthase, and heat then decarboxylates CBCA into CBC. CBCA's formula is C22H30O4 (CAS 185505-15-1). Unheated material carries the acid; heating converts it to neutral CBC. (Zirpel 2018.)
Buying & trust
Show the answers 5
Where can I buy CBC?
Online from hemp and cannabinoid retailers, and in some dispensaries and wellness shops, usually inside full-spectrum oils or minor-cannabinoid blends rather than as isolate. We don't endorse specific brands. Wherever you buy, insist on a current third-party certificate of analysis (COA). (Not legal or medical advice.)
Why is CBC rare or expensive?
Because the plant makes little of it. CBC usually occurs in small concentrations, so isolating useful quantities takes more biomass and processing than CBD does. It also has to convert from CBCA, it can degrade (to CBL under light, for example), and demand is niche. Low yield plus extra purification make CBC costlier and less common.
How do I know a CBC product is real (COA / lab test)?
Ask for a current third-party certificate of analysis (COA) tied to the product's batch. A good COA lists cannabinoid content, confirming the actual CBC level, shows the THC level, and screens for contaminants (pesticides, heavy metals, residual solvents, microbials). The label should match the COA. Without a COA, walk away.
Is CBC worth trying?
Your call, but know how little is known. CBC's identity and laboratory pharmacology are verified, but no human trial establishes its benefits or safety, and the effects it is marketed for are preclinical only. Anyone who tries it should choose COA-verified products and consult a clinician first. (Not medical advice.)
What should I look for when buying CBC?
A current third-party COA that matches the batch comes first, then a clearly stated CBC content, a THC level within legal limits (which also matters for drug tests), and clean contaminant screening for pesticides, heavy metals, solvents and microbials. Favour brands that publish this openly, note whether the product is isolate or full-spectrum, and be sceptical of health claims. (Not medical advice.)
References
Where every CBC claim comes from
The three papers cited on this page, and what each one tested. None is a graded record in our registry yet, and each is labelled as off-registry.
Show all 3 papers, with PubMed and DOI
2013
The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis
Preclinical · mouse macrophages + murine colitis model
2011
Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation
Preclinical · gene expression in mouse intestine
2013
The effect of cannabichromene on adult neural stem/progenitor cells
In vitro · mouse neural stem/progenitor cells
Before you act on what you read about CBC
Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.
Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.
Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.
Report a safety event → Compound monographs
The rest of the family.
Seven compounds, each with its own monograph. The line under each one is what the verified registry actually holds for it — including where that is nothing yet.
Cannabigerol (CBG)
The mother cannabinoid. CBGa decarboxylates to CBG, and both occur in the plant. The three synthases act on CBGa, the acid, branching it into THC, CBD and CBC. CBG carries more evidence than any other compound on the platform.
Cannabigerolic acid (CBGa)
The acid CBG comes from, and the shared substrate the three branch synthases compete for. Heat decarboxylates it to CBG.
Cannabigerovarin (CBGV)
The propyl (varin) analogue of CBG, with a three-carbon side chain in place of five.
Cannabinol (CBN)
Forms as THC ages and oxidises, so it builds up in stored material rather than being made by the plant directly.
Cannabidivarin (CBDV)
CBD's propyl analogue, and the varin with the largest published human trial record.
Tetrahydrocannabivarin (THCV)
THC's propyl analogue, which in laboratory work behaves differently from THC at its receptors.
Keep exploring
Families
Its acid or neutral form